DOP2003000747A - Composiciones oftalmicas para el tratamiento de la hipertension ocular - Google Patents

Composiciones oftalmicas para el tratamiento de la hipertension ocular

Info

Publication number
DOP2003000747A
DOP2003000747A DO2003000747A DO2003000747A DOP2003000747A DO P2003000747 A DOP2003000747 A DO P2003000747A DO 2003000747 A DO2003000747 A DO 2003000747A DO 2003000747 A DO2003000747 A DO 2003000747A DO P2003000747 A DOP2003000747 A DO P2003000747A
Authority
DO
Dominican Republic
Prior art keywords
treatment
eye
ophthalmic compositions
eye hypertension
compounds
Prior art date
Application number
DO2003000747A
Other languages
English (en)
Inventor
James B Doherty
Meng Hsin Chen
Luping Liu
Swaminathan Natarajan
Robert M Tynebor
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of DOP2003000747A publication Critical patent/DOP2003000747A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se relaciona con compuestos potentes bloqueadores del canal de potasio de formula I o una formulación de ellos para el tratamiento del glaucoma y otras condiciones las cuales conducen a elevar la presión intraocular en el ojo de un paciente. Estas invención tambien se relaciona con el uso de tales compuestos para dar un efecto neuroprotector al ojo de especies mamíferas, particularmente humanos.
DO2003000747A 2002-11-08 2003-11-07 Composiciones oftalmicas para el tratamiento de la hipertension ocular DOP2003000747A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42480802P 2002-11-08 2002-11-08
US50009103P 2003-09-04 2003-09-04

Publications (1)

Publication Number Publication Date
DOP2003000747A true DOP2003000747A (es) 2004-05-31

Family

ID=32314559

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2003000747A DOP2003000747A (es) 2002-11-08 2003-11-07 Composiciones oftalmicas para el tratamiento de la hipertension ocular

Country Status (22)

Country Link
US (2) US7196082B2 (es)
EP (1) EP1562909B1 (es)
JP (2) JP4456072B2 (es)
KR (1) KR20050072805A (es)
AR (1) AR041991A1 (es)
AU (2) AU2003287506B8 (es)
BR (1) BR0316040A (es)
CA (1) CA2505086C (es)
CL (1) CL2003002293A1 (es)
DO (1) DOP2003000747A (es)
EC (1) ECSP055781A (es)
HR (1) HRP20050409A2 (es)
IS (1) IS7822A (es)
MA (1) MA27497A1 (es)
MX (1) MXPA05004889A (es)
NO (1) NO20052751L (es)
NZ (1) NZ539593A (es)
PE (1) PE20040692A1 (es)
PL (1) PL377172A1 (es)
RU (1) RU2005117627A (es)
TW (1) TWI250873B (es)
WO (2) WO2004043932A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040028469A (ko) 2002-09-30 2004-04-03 엘지전자 주식회사 1 회 기록 가능한 광디스크의 디펙트 영역 관리방법
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
KR20060090801A (ko) * 2003-09-04 2006-08-16 머크 앤드 캄파니 인코포레이티드 고안압증 치료용 안용 조성물
CN1988903A (zh) * 2004-07-20 2007-06-27 默克公司 用于治疗高眼压症的眼用组合物
EP1647549A1 (en) 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
ATE542800T1 (de) * 2006-01-31 2012-02-15 Array Biopharma Inc Kinasehemmer und ihre anwendungsverfahren
AU2007227664A1 (en) * 2006-03-13 2007-09-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
JP5255559B2 (ja) * 2006-03-31 2013-08-07 アボット・ラボラトリーズ インダゾール化合物
EP2352501B1 (en) * 2008-11-03 2014-01-01 ChemoCentryx, Inc. Compounds for use in the treatment of osteoporosis
WO2012071369A2 (en) 2010-11-24 2012-05-31 The Trustees Of Columbia University In The City Of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US9637450B2 (en) 2013-03-14 2017-05-02 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
EP3495357B1 (en) * 2013-03-14 2021-05-05 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
CA2947174C (en) 2014-04-30 2023-02-28 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparaiton and use
CN104211638A (zh) * 2014-08-13 2014-12-17 李增 一种脂肪氨基取代的芸香碱类衍生物及其制备和作为抗阿尔兹海默症的药物中的应用
EP3402780A1 (en) 2016-01-14 2018-11-21 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) * 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
AU3693789A (en) 1988-05-10 1989-11-29 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) New ophthalmic preparation for treating glaucoma
EP0569046B1 (en) * 1988-09-06 2002-11-13 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
JP3208210B2 (ja) * 1993-03-17 2001-09-10 旭化成株式会社 結晶性芳香族ポリカーボネートプレポリマーの製造方法及び芳香族ポリカーボネートの製造方法
EP0724443A4 (en) 1993-06-08 1997-09-10 Vide Pharmaceuticals METHOD AND PREPARATIONS FOR LOWERING THE EYE PRESSURE
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5573758A (en) 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
AP2001002304A0 (en) * 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
US5925342A (en) * 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
WO2000015608A1 (en) 1998-09-14 2000-03-23 Ono Pharmaceutical Co., Ltd. φ-SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
MXPA02006322A (es) 1999-12-22 2002-12-13 Pfizer Prod Inc Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
EP1251862B1 (en) 2000-01-18 2008-10-01 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
KR20030095183A (ko) 2000-03-17 2003-12-18 알콘, 인코퍼레이티드 녹내장 치료용 5-하이드록시 인다졸 유도체
AU2001216072A1 (en) 2000-03-17 2001-10-03 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US6956036B1 (en) * 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
CN1366458A (zh) 2000-03-31 2002-08-28 东丽株式会社 毛发生长和毛发形成调节剂
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
ATE374182T1 (de) 2000-11-27 2007-10-15 Pfizer Prod Inc Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose
FR2827861B1 (fr) 2001-07-27 2004-04-02 Aventis Pharma Sa Derives des indazoles ou des indoles, leur utilisation en medecine humaine et plus particulierement en cancerologie

Also Published As

Publication number Publication date
TW200501949A (en) 2005-01-16
AU2003287506B8 (en) 2009-05-28
US20070129418A1 (en) 2007-06-07
MXPA05004889A (es) 2005-07-22
AU2003286884A1 (en) 2004-06-03
CL2003002293A1 (es) 2005-01-14
MA27497A1 (fr) 2005-08-01
KR20050072805A (ko) 2005-07-12
JP5061293B2 (ja) 2012-10-31
CA2505086C (en) 2009-08-25
PL377172A1 (pl) 2006-01-23
TWI250873B (en) 2006-03-11
EP1562909B1 (en) 2012-06-27
NO20052751D0 (no) 2005-06-07
US20040097575A1 (en) 2004-05-20
JP2006508190A (ja) 2006-03-09
EP1562909A1 (en) 2005-08-17
NZ539593A (en) 2006-12-22
PE20040692A1 (es) 2004-10-08
RU2005117627A (ru) 2006-01-20
US7547720B2 (en) 2009-06-16
JP2010006825A (ja) 2010-01-14
AU2003287506B2 (en) 2009-04-23
IS7822A (is) 2005-04-25
CA2505086A1 (en) 2004-05-27
ECSP055781A (es) 2005-09-20
JP4456072B2 (ja) 2010-04-28
AU2003287506A1 (en) 2004-06-03
WO2004043932A1 (en) 2004-05-27
WO2004043933A1 (en) 2004-05-27
AR041991A1 (es) 2005-06-08
US7196082B2 (en) 2007-03-27
HRP20050409A2 (en) 2006-02-28
BR0316040A (pt) 2005-09-13
NO20052751L (no) 2005-06-07

Similar Documents

Publication Publication Date Title
ECSP055781A (es) Composiciones oftálmicas para el tratamiento de la hipertensión ocular
UY30058A1 (es) (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa
MXPA03008401A (es) Combinacion de brimonidina y timolol para uso oftalmico, topico.
WO2007108968A3 (en) Ophthalmic compositions for treating ocular hypertension
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
ECSP056037A (es) Agonista del receptor ep4, composiciones y procedimientos del mismo
CR10041A (es) Uso de vías inhibitorias coplementarias para el tratamiento de enfermedades oculares
WO2017158365A3 (en) Ophthalmic delivery device and ophthalmic active agent containing compositions
CY1105877T1 (el) Οφθαλμικες συνθεσεις πepιεχουσες συνepγιστικο συνδυασμο τριων πολυμepων
NZ588938A (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
WO2005020917A3 (en) Ophthalmic compositions for treating ocular hypertension
MX359415B (es) Composiciones oftalmicas que comprenden povidona-yodo.
ECSP12012037A (es) Composiciones oftálmicas no irritantes de iodopovidona
CL2004000412A1 (es) Uso de un compuesto antagonista selectivo del receptor ep2 para tratar hipertension pulmonar.
TW200626132A (en) Topical nepafenac formulations
TW200700392A (en) Novel compounds
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
DE602006003438D1 (de) Ophthalmische suspension aus einem ophthalmischen arzneimittel, einem poloxamin und glykol-tonizitätsanpassenden mittel, verwendung der zusammensetzung zur herstellung eines medikaments zur behandlung von augenerkrankungen
AR032138A1 (es) Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma
MX2020003534A (es) Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
EP1251862A4 (en) ORTHALMOLOGICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR HYPERTENSION
WO2007146136A3 (en) Ophthalmic compositions for treating ocular hypertension
NI201200112A (es) Combinacion triple para reduccion de presion intraocular
AR018272A1 (es) Una composicion oftalmica para el tratamiento de las lesiones de la cornea causadas por diabetes y/o para el tratamiento de la estesia de la corneadeteriorada y el uso del ingrediente activo de dicha composicion para la preparacion de dicha composicion oftalmica.
BRPI0517972A (pt) ácido 5,6,7-triidroxiheptanóico e análogos para o tratamento de doenças oculares e doenças associadas com respostas hiperproliferativas e angiogênicas